

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-31. (Canceled)

Claim 32. (Previously Presented) A method of inhibiting the IL-5, IL-3 or GM-CSF mediated leukaemic cell proliferation by contacting the leukaemic cells with monoclonal antibody or fragments thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor β_c , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the β_c subunit.

Claim 33. (Currently Amended) A method of **claim 32, inhibiting the IL-5, IL-3 or GM-CSF mediated leukaemic cell proliferation as in the claim 32** wherein the monoclonal antibody or fragments thereof are BION-1 or fragments thereof.

Claim 34. (Previously Presented) A method of inhibiting the IL-5, IL-3 or GM-CSF mediated eosinophil activation, eosinophil production or eosinophil survival, by contacting the eosinophils with monoclonal antibody or fragments thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor β_c , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the β_c subunit.

Claim 35. (Currently Amended) A method of **claim 34, inhibiting the IL-5, IL-3 or GM-CSF mediated eosinophil activation, eosinophil production or eosinophil survival as in the claim 32** wherein the monoclonal antibody or fragments thereof are BION-1 or fragments thereof.

Claims 36-39. Canceled.

- Claim 40. (New) A method of treating leukemia, comprising administering a monoclonal antibody or fragments thereof to an individual in need thereof, wherein said monoclonal antibody or fragments thereof are capable of inhibiting the binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor β_c , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the β_c subunit.
- Claim 41. (New) A method of claim 40, wherein the monoclonal antibody or fragments thereof are BION-1 or fragments thereof.
- Claim 42. (New) A method of treating asthma, comprising administering a monoclonal antibody or fragments thereof to an individual in need thereof, wherein said monoclonal antibody or fragments thereof are capable of inhibiting the binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor β_c , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the β_c subunit.
- Claim 43. (New) A method of claim 42, wherein the monoclonal antibody or fragments thereof are BION-1 or fragments thereof.